Stock TRVI TREVI THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Market Closed - Nasdaq
Other stock markets
 01:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
2.94 USD +5.76% Intraday chart for Trevi Therapeutics, Inc. 0.00% +119.40%
20/03 Transcript : Trevi Therapeutics, Inc., Q4 2023 Earnings Call, Mar 20, 2024
20/03 Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Trevi Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

68d362f428a5c950fcda9.FNeZLC_16LmWAb7FYR9eu0UuyLWbKYcgiUsx62R717I.RuL8e2meh9fsVeutOHMwijZFptDOGOVn7wN1jA4prvBTldoVdbu3769Djg~5e04c61e81dcb0bbfdcd146581e498ab

Analyst Recommendations on Trevi Therapeutics, Inc.

B. Riley Starts Trevi Therapeutics at Buy With $6 PT, Views as Deep Value Play in Idiopathic Pulmonary Fibrosis Chronic Cough Space MT
JonesTrading Initiates Trevi Therapeutics at Buy With $7 Price Target MT
SVB Securities Starts Trevi Therapeutics at Outperform With $6 Price Target MT
Oppenheimer Adjusts Trevi Therapeutics Price Target to $9 From $12 Mainly on Higher Discount Rate, Maintains Outperform Rating MT
Needham Trims Price Target on Trevi Therapeutics to $8 From $10, Maintains Buy Rating MT
Oppenheimer Adjusts Trevi Therapeutics' Price Target to $12 From $10, Maintains Outperform Rating MT
Needham Adjusts Trevi Therapeutics' Price Target to $10 From $8, Reiterates Buy Rating MT
Trevi Therapeutics Rises After Oppenheimer Starts Coverage With Outperform Rating MT
Oppenheimer Starts Trevi Therapeutics at Outperform With $10 Price Target MT
Aegis Capital Initiates Trevi Therapeutics at Buy with $10 Price Target MT
Needham Adjusts Price Target on Trevi Therapeutics to $8 from $10, Keeps Buy Rating MT
TREVI THERAPEUTICS : Needham Adjusts Trevi Therapeutics' Price Target to $10 from $12, Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.94 USD
Average target price
7.4 USD
Spread / Average Target
+151.70%
High Price Target
9 USD
Spread / Highest target
+206.12%
Low Price Target
6 USD
Spread / Lowest Target
+104.08%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Trevi Therapeutics, Inc.

B. Riley
JonesTrading Institutional Services
SVB Securities LLC
Oppenheimer
Needham & Co.
Aegis Capital

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TRVI Stock
  4. Consensus Trevi Therapeutics, Inc.